Paul Reider has followed Coherus BioSciences’ last biosimilar product out the door. | Paul Reider has followed Coherus ...

Election Commission data shows growth in political donations, with BJP receiving majority; corporate trusts dominate ...

Private equity activity in healthcare remained resilient with 42 deals worth $562 million, just shy of last quarter’s $603 ...

India's pharma and healthcare sector demonstrates resilient investor interest, marked by a 34% year-on-year increase in deal ...

Dr. Kiran Mahasuar, Asst Professor at IMT Ghaziabad, writes why branded generics may still dominate volumes, but the real ...

But these same areas are now overcrowded, and price wars are common. Companies like Mankind, Sun Pharma, and Intas are looking at combinations of brand innovation, portfolio reshuffling ...

DelveInsight's "Uterine Sarcoma Market Insights, Epidemiology, and Market Forecast- 2032" report delivers an in-depth ...

London-headquartered Accord is one of the largest suppliers of chemotherapy products in Europe and is a wholly-owned subsidiary of India's Intas Pharma, which has annual revenues of around $3.4 ...

EU & Emerging markets post signing the LOI by INTAS Pharmaceuticals as its fully owned subsidiary Sakar Healthcare Limited has informed the Exchange about Certificate under Regulation 74 (5) of the ...

Of the 12,000 new positions, nearly 6,500 will be in construction and 1,000 at new and expanded facilities, the Swiss pharma giant said. Once capacity comes online at the various facilities ...